Updates are available Correction dated 2024-03-18
Click to view Correction: https://doi.org/10.1038/s41586-024-07277-4
-
Authors
Han, Guangchun http://orcid.org/0000-0001-9277-2507
Sinjab, Ansam http://orcid.org/0000-0001-5777-227X
Rahal, Zahraa
Lynch, Anne M.
Treekitkarnmongkol, Warapen http://orcid.org/0000-0002-7542-5201
Liu, Yuejiang http://orcid.org/0000-0003-1432-3938
Serrano, Alejandra G.
Feng, Jiping
Liang, Ke
Khan, Khaja
Lu, Wei
Hernandez, Sharia D.
Liu, Yunhe http://orcid.org/0000-0002-2120-952X
Cao, Xuanye http://orcid.org/0000-0002-2181-3540
Dai, Enyu
Pei, Guangsheng
Hu, Jian
Abaya, Camille
Gomez-Bolanos, Lorena I. http://orcid.org/0000-0001-5132-4417
Peng, Fuduan
Chen, Minyue http://orcid.org/0000-0001-5721-5107
Parra, Edwin R. http://orcid.org/0000-0001-9068-1636
Cascone, Tina http://orcid.org/0000-0003-3008-5407
Sepesi, Boris http://orcid.org/0000-0003-1442-611X
Moghaddam, Seyed Javad http://orcid.org/0000-0002-5350-307X
Scheet, Paul http://orcid.org/0000-0002-5173-7497
Negrao, Marcelo V. http://orcid.org/0000-0001-8938-6699
Heymach, John V. http://orcid.org/0000-0001-9068-8942
Li, Mingyao http://orcid.org/0000-0001-8180-0621
Dubinett, Steven M. http://orcid.org/0000-0003-3656-8039
Stevenson, Christopher S.
Spira, Avrum E.
Fujimoto, Junya http://orcid.org/0000-0003-4813-3163
Solis, Luisa M. http://orcid.org/0000-0002-1253-630X
Wistuba, Ignacio I.
Chen, Jichao http://orcid.org/0000-0003-2749-8550
Wang, Linghua http://orcid.org/0000-0001-9380-0266
Kadara, Humam http://orcid.org/0000-0003-2976-9115
- License Information
-
More Information
Article History
Received: 10 May 2022
Accepted: 24 January 2024
First Online: 28 February 2024
Change Date: 18 March 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-024-07277-4
Competing interests
: C.S.S. and A.E.S. are employees of Johnson & Johnson. H.K. reports research funding from Johnson & Johnson. M.V.N. receives research funding to institution from Mirati, Novartis, Checkmate, Alaunos/Ziopharm, AstraZeneca, Pfizer and Genentech, and consultant/advisory board fees from Mirati, Merck/MSD and Genentech. T.C. reports speaker fees/honoraria from The Society for Immunotherapy of Cancer, Bristol Myers Squibb, Roche, Medscape and PeerView; travel, food and beverage expenses from Dava Oncology and Bristol Myers Squibb; advisory role/consulting fees from MedImmune/AstraZeneca, Bristol Myers Squibb, EMD Serono, Merck & Co., Genentech, Arrowhead Pharmaceuticals and Regeneron; and institutional research funding from MedImmune/AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim and EMD Serono. S.J.M. reports funding from Arrowhead Pharma and Boehringer Ingelheim outside the scopes of submitted work. B.S. reports consulting and speaker fees from PeerView, AstraZeneca and Medscape, and institutional research funding from Bristol Myers Squibb. J.V.H. reports fees for advisory committees/consulting from AstraZeneca, EMD Serono, Boehringer-Ingelheim, Catalyst, Genentech, GlaxoSmithKline, Hengrui Therapeutics, Eli Lilly, Spectrum, Sanofi, Takeda, Mirati Therapeutics, BMS, BrightPath Biotherapeutics, Janssen Global Services, Nexus Health Systems, Pneuma Respiratory, Kairos Venture Investments, Roche, Leads Biolabs, RefleXion, Chugai Pharmaceuticals; research support from AstraZeneca, Bristol-Myers Squibb, Spectrum and Takeda, and royalties and licensing fees from Spectrum. I.I.W. reports grants and personal fees from Genentech/Roche, grants and personal fees from Bayer, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from AstraZeneca, grants and personal fees from Pfizer, grants and personal fees from HTG Molecular, personal fees from Asuragen, grants and personal fees from Merck, grants and personal fees from GlaxoSmithKline, grants and personal fees from Guardant Health, personal fees from Flame, grants and personal fees from Novartis, grants and personal fees from Sanofi, personal fees from Daiichi Sankyo, grants and personal fees from Amgen, personal fees from Oncocyte, personal fees from MSD, personal fees from Platform Health, grants from Adaptive, grants from Adaptimmune, grants from EMD Serono, grants from Takeda, grants from Karus, grants from Johnson & Johnson, grants from 4D, from Iovance and from Akoya, outside the submitted work. All other authors declare no competing interests.
